Max Hardy-Werbin
Impact in
-
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
-
- Cancer Genomics and Diagnostics
Papers in
- Oncology 12
- Lung Cancer Research Studies 6
- Cancer Immunotherapy and Biomarkers 4
- Peptidase Inhibition and Analysis 3
-
- Lung Cancer Treatments and Mutations 7
- Lung Cancer Diagnosis and Treatment 2
- Co-authors
- Edurne Arriola (17 shared papers)Pedro Rocha (13 shared papers)Álvaro Taus (14 shared papers)Joan Albanell (7 shared papers)Sergi Clavé (8 shared papers)Marta Salido (8 shared papers)Lara Pijuán (5 shared papers)Christian H. Ottensmeier (4 shared papers)
- Journals
- Journal of Thoracic Oncology (3 papers)Annals of Oncology (3 papers)Clinical Lung Cancer (2 papers)Scientific Reports (2 papers)OncoImmunology (2 papers)
- Partner nations
- SpainUnited KingdomUnited States
In The Last Decade
Max Hardy-Werbin
20 papers receiving 312 citations
Peers
Comparison fields: 5 of 39
- Oncology 191
- Cancer Research 67
- Pulmonary and Respiratory Medicine 104
- Immunology 43
- Health Informatics 2
Countries citing papers authored by Max Hardy-Werbin
This map shows the geographic impact of Max Hardy-Werbin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Hardy-Werbin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Hardy-Werbin more than expected).
Fields of papers citing papers by Max Hardy-Werbin
This network shows the impact of papers produced by Max Hardy-Werbin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Hardy-Werbin. The network helps show where Max Hardy-Werbin may publish in the future.
Co-authors
The 25 scholars most cited alongside Max Hardy-Werbin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 70 | |
| 2 | 2019 | 68 | |
| 3 | 2018 | 45 | |
| 4 | 2017 | 29 | |
| 5 | 2018 | 24 | |
| 6 | 2019 | 20 | |
| 7 | 2019 | 14 | |
| 8 | 2019 | 11 | |
| 9 | 2023 | 9 | |
| 10 | 2019 | 4 | |
| 11 | 2023 | 4 | |
| 12 | 2020 | 4 | |
| 13 | 2023 | 2 | |
| 14 | 2020 | 2 | |
| 15 | 2015 | 2 | |
| 16 | 2021 | 2 | |
| 17 | 2016 | 1 | |
| 18 | 2019 | 1 | |
| 19 | 2018 | 1 | |
| 20 | 2017 | 1 |
About Max Hardy-Werbin
Max Hardy-Werbin is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 21 papers that have together received 314 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (6 papers), Cancer Immunotherapy and Biomarkers (4 papers), Peptidase Inhibition and Analysis (3 papers), Cancer Genomics and Diagnostics (2 papers), Lung Cancer Diagnosis and Treatment (2 papers), Radiomics and Machine Learning in Medical Imaging (2 papers) and Liver physiology and pathology (1 paper). The work is most often cited by research in Oncology (191 citations), Cancer Research (67 citations), Pulmonary and Respiratory Medicine (104 citations), Immunology (43 citations) and Health Informatics (2 citations). Max Hardy-Werbin has collaborated with scholars based in Spain, United Kingdom and United States. Frequent co-authors include Edurne Arriola, Pedro Rocha, Álvaro Taus, Joan Albanell, Sergi Clavé, Marta Salido, Lara Pijuán, Christian H. Ottensmeier, Deborah Joseph-Pietras and Ana Rovira. Their work appears in journals such as Journal of Thoracic Oncology, Annals of Oncology, Clinical Lung Cancer, Scientific Reports and OncoImmunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.